Cytokinetics (United States)

Cytokinetics (United States)

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Cytokinetics (United States), United States, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

59%


Total
Publications

358


Total Open
Publications

211


Total
Citations

15K


Open Access
Percentage

59%


Total
Publications

358


Total Open
Publications

211


Total
Citations

15K

Wikipedia

Website

download

Breakdown

23% 26% 10% 41%

Publisher Open

23%

Both

26%

Other Platform Open

10%

Closed

41%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

05101520253035Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

17%OA Journal

OA Journal 17%

29

Hybrid 44%

76

No Guarantees 39%

69

Other Platform Open

Domain 78%

100

Institution 34%

43

Public 9%

12

Other Internet 9%

12

Preprint 5%

7

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
100
Europe PMC
Domain
62
The University of Glasgow - Enlighten: Publications
Institution
11
Figshare
Public
8
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
7
University of California - eScholarship University of California
Institution
7
Semantic Scholar
Public
7
Le Centre pour la Communication Scientifique Directe - HAL - Inria
Institution
4
California Digital Library - eScholarship
Other Internet
4
bioRxiv
Preprint
4
1 / 6

Data updated 13 August 2024

Share

Share

Share